SmartCell Center offers multiple sclerosis (MS) treatment using fetal stem cells, with improvements reported in most cases. The goal of MS treatment is to terminate autoimmune aggression, that is, the internal attack against patient’s own nervous system, by disrupting the main mechanism of the disease. This, in turn, leads to the subsiding or even regression of neurological symptoms.
With MS, fetal stem cells have 2 major functions:
- prevention of nerve cell damage: Stem cells are able to help reduce or even prevent damage caused to nerve cells. This process is called “neuroprotection.”
- repair of damaged myelin: In MS, the protective myelin layer surrounding nerve fibers is damaged by the person’s own immune system. Specialized stem cells in the brain can generate myelin-producing cells, which facilitates the repair of myelin. This process is known as “remyelination.”
Over the last six years, SmartCell Center has treated more than 150 patients with different forms of MS and achieved improvements in 78% of cases.
After stem cell treatment, our patients report a number of improvements:
- stabilized condition and the course of the disease alleviated;
- shorter exacerbation period and longer remissions;
- less spasticity in the extremities;
- better gait, coordination and balance;
- improved speech;
- psychoemotional and cognitive improvements;
- boosted immune system;
- improved functioning in the heart, kidneys, liver and bowel;
- better quality of life;
- a chance to return to work if treatment is during the early stages of MS.
Restoring the nervous system takes time and requires patience. A customized and integrated MS treatment at SmartCell Center lasts 5 days.
Results of fetal stem cell treatment of multiple sclerosis
Four main subtypes of clinical course of multiple sclerosis (MS) have been described.
The first type, relapsing-remitting MS, is characterized by unpredictable relapses of neurological deficits. The attacks develop within periods of days to weeks and can be followed by full or partial resolve of deficits, or absence of remission. Remission after attacks usually develops in a few weeks or months after the peak of the disease, although sometimes recovery can take two years and more. Patients with such course of the disease do not report neurological deficit progression between the attacks. In most patients, this describes the initial course of MS.
In the second subtype, secondary progressive MS, the disease initially presents the picture of relapsing-remitting MS but progresses with the course of time. Period of progression can develop either just after the onset of the disease or in several years or decades. Secondary progressive subtype differs from relapsing-remitting MS by gradual progression of the deficits between the attacks or by the gradual progression of the deficits after the attacks become indistinguishable.
The third subtype, primary progressive MS, is characterized by the gradual progression of disability from onset. Some individuals can present periods of clear stability but do not suffer severe attacks.
The primary progressive MS develops in about 15% of multiple sclerosis cases and is the most frequent form of late onset MS (after the age of 40). Sometimes, patients with clear primary progressive MS also suffer superimposed attacks. This non-standard clinical picture is referred to as progressive relapsing MS.
Observed were 13 cases with remitting–relapsing multiple sclerosis, among them 5 female patients and 8 male patients. Age of patients varied from 19 to 28, mean age being 25.3±2.47 years. Duration of the diagnosed multiple sclerosis varied form 8 months to 3.5 years (mean 2.13±0.26 years). Duration of remission in this group lasted from 2 months to 1 year, usually being 3-6 months. Since the onset, we observed worsening of symptoms and residual effects from attack to attack in most patients (10 individuals).
Clinical symptoms in MS patients were evaluated using the 4-score scale: 0 – absence of sign; 1 – mild sign; 2 – moderate sign; 3 – severe sign; 4 – extremely severe sign. The Table 1 presents the mean score in patients demonstrating a certain sign and the number of such patients (N). The symptoms were evaluated during the remission.
By the beginning of the fetal stem cell transplantation, this group of patients most frequently demonstrated pyramidal, sensory and visual disturbances of different degree (Table 1).
Table 1. Clinical Profile of Patients with Remitting-Relapsing MS (n=13)
|Symptom||N||Symptom intensity, score (0–4) |
|After transplantation, years|
|elevation of deep reflexes||6||3||3–2||2||2–1||2–1|
|diminished superficial abdominal reflexes||6||3–2||2||2||2–1||2–1|
|pathological extensor plantar reflexes||5||2||2||2||2–1||2–1|
|Weakness in the extremities||6||2||2–1||1||1||1|
|slowed information processing||4||2||2–1||2–1||1||1|
|Dizziness and vomiting||3||2||1||1||0||0|
After the stem cell treatment, this group of patients demonstrated gradual reduction in clinical manifestations of the focal lesions of the central nervous system. Significant positive dynamics was noticed in such symptoms as nystagmus, convergence disturbance, spasticity, coordination disorders, depression and cognitive dysfunction. Usually, these disturbances resolved within the first year of our follow up after the transplantation.
Other disturbances were more resistant, their manifestations persisted during several years, and their reduction was not so clear. These are such manifestations as dysarthria, dysphagia, pathological reflexes and ataxia. These differences must be due to different degree and location of the damage in the central nervous system.
Stem cell treatment significantly improved mental state of MS patients, and we believe this effect is due not only to neurological improvement that gave the patients a hope for recovery after the continuous inefficient routine treatment but also due to the positive effect of fetal stem cells on the emotional sphere.
During the observation period (2 to 5 years) no exacerbations were noticed in this group of patients, although most of them suffered them regularly before the treatment. No disease progression as well as progression-related increased disability was observed either.
MRI results demonstrated the decrease of foci volume in the mean by 31%, decrease in number of foci following the gadolinium contrast by 48%, and reduction of the specific density of the foci in T2-regime. This evidences for the significant improvement of demyelinisation processes in the central nervous system.
Immunological test results (in 8 patients of the group) before the beginning of the fetal stem cell treatment showed depression of T-cell immunity – evident decrease of average number of CD3+lymphocytes (by 20.1%), CD8+lymphocytes (by 15.4%), increase of immunoregulatory index (by 15.3%), and activation of humoral immunity (elevation in lymphocyte count with CD19+ phenotype (in the mean by 38.1%), and class G immunoglobulins by 32.7% (p<0.05). Other indices didn’t have significant deviations from the reference rate (Table 2).
After fetal stem cell transplantation, the average level of lymphocytes with CD3+ phenotype has reliably increased in comparison with the initial level, although it was still lower than normal by 9.0% (p<0.05). In 6 months after the treatment, this index increased in the mean by 5.7% and statistically didn’t differ from the norm.
T-helpers (CD4+) demonstrated mild and unreliable tendency for elevation. Within 6 months, their number gradually increased on average by 7.7%.
The number of T-suppressors (CD8+lymphocytes) in one month after the transplantation increased and statistically didn’t differ from the norm, and in 6 months after the transplantation their level elevated again (in the mean by 20.5%) and achieved the initial level.
Immunoregulatory index reflected definite shifts of the cell immunity and increased with the elevation of the CD8+lymphocyte level. In one month after the transplantation, the average immunoregulatory index was 1.74±0.05, i.e. it decreased by 7.6%, and in 6 months after the treatment it remained stable.
The decrease in CD19+ lymphocyte level that was initially increased was noticed in one month after the transplantation (by 17.2%). In 6 months, the average level of CD19+ lymphocytes was reported to decrease more, in the mean by 21.7% (p<0.05), in comparison with the initial level.
Class G immunoglobulins level also gradually decreased, and in one month after the transplantation it reduced by 12.0%, and in 6 months – by 19.3%.
Thus, we can conclude that fetal stem cell transplantation has a significant immunomodulatory effect on the immune system of MS patients. Our study confirmed the elevation of the lowered indices of the cell immunity and decrease of the elevated indices of the humoral immunity (CD19+lymphocytes and IgG) in one month after the fetal stem cell transplantation, and this tendency persisted within the period of our study (6 months).
Table 2. Immunity Indices in Patients with Remitting-Relapsing Multiple Sclerosis (n=8)
|Indices||Reference Rate |
|Before transpl. ||After transplantation|
|In 1 month||In 6 months|
Note: * – validity coefficient in comparison with the reference rate p<0,05; # – validity coefficient in comparison with the rate before the transplantation p<0,05.
Observed were 11 patients with secondary progressive multiple sclerosis, among them 6 female patients and 5 male patients. Patients’ age varied from 17 to 38, mean age being 31.4±4.32 years. Duration of the diagnosed disease by the beginning of the therapy was 1 to 5.5 years, mean duration being 2.96±0.24 years. This group of patients reported persistent progress of neurological symptomatology from attack to attack and during the periods of remission. 4 cases suffered stable disability and ambulated in a wheelchair.
Clinical symptoms in MS patients were evaluated using the 4-score scale: 0 – absence of sign; 1 – mild sign; 2 – moderate sign; 3 – severe sign; 4 – extremely severe sign. The Table presents the mean score in patients demonstrating a certain sign and the number of such patients (N). The symptoms were evaluated during the remission.
All the patients tolerated the fetal stem cell transplantation well.
Syndrome of early posttransplantation improvements was observed in 7 cases (63.6%).
Table 1. Clinical Profile of Patients with Remitting-Relapsing MS (n=11)
|Symptom||N||Symptom intensity, score (0–4) |
|After transplantation, years|
|elevation of deep reflexes||7||3||3||2||2||2–1|
|diminished superficial abdominal reflexes||7||3||2||2||2||2–1|
|pathological extensor plantar reflexes||5||3–2||2||2||2||2|
|Weakness in the extremities||7||3||2||2–1||1||1|
|slowed information processing||5||2||2–1||2–1||1||1|
|Dizziness and vomiting||2||3–2||1||0||0||0|
This group of patients demonstrated more severe main symptoms on the day of treatment and was more resistant to the applied therapy compared to patients in the remitting-relapsing group, although clear positive dynamics was observed in all the manifestations of the disease.
Treatment effectiveness was different in different symptoms. We noticed the same regularity as in the remitting-relapsing group: ophthalmological, mental and emotional disturbances responded to our therapy better (during the first year after the transplantation) in comparison with the spinal and cerebellar disorders.
This group of patients didn’t report exacerbation or further progression of the disease within the whole period of observations (1 to 4 years).
MRI results showed the decrease of foci following the gadolinium contrast by 42%, reduction in the foci volume by 44%, and decrease of the specific density in T2-regime.
Observed were 3 male patients with primary progressive multiple sclerosis. Patients’ age was 31 to 38 years, mean age being 36,4±4,32 years. The diagnosis was established 1,5 to 3 years prior to the cell therapy. In this group of patients, observed was rapid progression of the neurological symptomatology since the first exacerbation, but clear exacerbation and remission were not reported thereafter.
By the beginning of the therapy, the patients demonstrated pronounced symptoms of the brainstem and cerebellum damage as well as spinal disturbances. All the patients reported depression.
Stem cell treatment in this group of patients resulted in termination of the disease progression within 3-6 months, although marked regression of the previous neurological symptoms was not achieved. Reported were significantly improved emotional state and intellectual functioning.
According to MRI results, following gadolinium contrast, registered was decreased number of foci by 51%, and decreased foci volume by 37%.
In the course of 4 years after the first stem cell treatment, observed were 18 multiple sclerosis patients. The table below presents the dynamics of neurological symptoms after the treatment.
Scale: 10→0 points (positive dynamics)
|Before transplantation||After transplantation, year|
|Half year||Half year||Half year||Half year|
|Ocular convergence disturbance||10||1–0||1–0||0||0||0||0||0||0|
|Muscle hypertonus in the extremities||10||7–6||5–3||3||3||3||2||2||2|
|Muscle hypotonus in the extremities||10||9||8||7||7||6||6||6||6|
|Coordination tests |
(finger-to-nose, heel-knee test,
standing in Romberg’s position)
|Deep reflexes (high) |
|Pathological plantar reflexes||10||10||10||10||10||9||9||9||9|
|Change of strength in arms and legs||10||5||5||4||4||4||4||3||3|
|Higher nervous activity ||10 |
Medical case reports
We had the honour to accept at the clinic Mr. D.C., DOB November 3, 1959, attended by Mrs. I.
Diagnosis: Multiple sclerosis of cerebrospinal type with tetraparesis, d>s, mostly in the legs. Concomitant divergent strabismus. Middle range nystagmus. Hypermetropic astigmatism. Angiopathy of retina. Initial maculodystrophy of both eyes.
Mr. D.C. received a course of cell therapy. The action of cell suspensions was directed to the restitution of nerve connections and normalization of hemato-encephalic barrier functions.
1st day. Implantation of the cell suspension sample 3038AM118 subcutaneously in the frontal abdomen in two depots in amount 1.0 ml each.
2nd day. Transplantation of the cell suspension sample 3038A118, IV, amount 2.0 ml. Implantation of the cell suspension sample 3038AM118 subcutaneously in the frontal abdomen in two depots in amount 1.0 ml each.
3rd day. Transplantation of the cell suspension sample 3038A118, IV, amount 2.5 ml. Implantation of the cell suspension sample 3038AM118 subcutaneously in the frontal abdomen in two depots in amount 0.7 ml each.
4th day. Transplantation of the cell suspension sample 3038A118, IV, amount 2.2 ml.
5th day. Transplantation of the cell suspension sample 3038A228, IV, amount 3.2 ml. Implantation of the cell suspension sample 3038AM228 subcutaneously in the frontal abdomen in two depots in amount 1.4 ml each.
The cell suspension samples 3038AM118, 3038A118, 3038AM228 and 3038A228 possess the mentioned above functional activity and are certified as follows:
|Bacterial sterility test||Negative|
|Test with cardiolipid antigen||Negative|
|Anti – HIV1/HIV2||Negative|
|Enzygnost Anti – HIV1/HIV2||Negative|
|Anti – HBc monoclonal||Negative|
|Anti – CMV/IgG+IgM||Negative|
|Anti – Rubella Virus/IgG||Negative|
Average blood count: Erythrocytes 4,95×1012/l, Hb 160 g/l, color index 1.0, thrombocytes 260×109/l, leukocytes 7.4×109/l, stab neutrophils 3%, segmented neutrophils 68%, eosinophiles 1%, lymphocytes 26%, monocytes 2%, ESR 3 mm/hr.
Blood chemistry: Bilirubin total 17.6 mmol/l, direct neg., indirect 17.6 mmol/l, ALT 0.32 mmol/l, ACT 0.21 mmol/l, thymol test 4.3 units, cholesterol 5.4. mmol/l, urea 6.2 mmol/l, creatinine 0.065 mmol/l.
Blood glucose 4.6 mmol/l.
Common urine analysis: Volume 180.0 ml, density 1018, transparent, light-yellow, protein – neg., sugar – neg., flat epithelium in small quantity, leukocytes 2-3 in the field of vision, mucus in small quantity, small amount of oxalates.
ECG on the 1st day of treatment: Regular sinus rhythm, normal position of heart axis, dystrophic changes in myocardium.
ECG on the 5th day of treatment: Regular sinus rhythm, diffuse changes of myocardium.
Examination by neurologist
The patient fell ill 4 years ago. He complaints of the inability to walk – the legs are heavy, constrained, he can stay only with the extrinsic aid due to ataxia and weakness of legs. Complaints on the disorders of sight – convergence is difficult, double vision (left eye flows aside at fixation). In neurological status is in contact, oriented. Divergent strabismus due to the left eye. Pupils d=s, photo reactions are torpid. Horizontal middle range nystagmus by the side look, s=d. The face is symmetric. Pharynx reflex is intact. The range of active movements in legs and arms is limited. Tonus in arms is increased insignificantly, in the legs -manifest spastic, reflexes enhanced, d>s, clonus in feet d>s, in both sides “fan” symptom. The pain sensitivity is intact, test for coordination executes sufficiently. According the results of MRI of cerebrum – multiple loci of lesion in truncus cerebry, corpus callosum. Conclusion: multiple sclerosis of cerebrospinal type with tetraparesis, d>s, mostly in legs, deterioration of vision.
Examination by ophthalmologist
At the approximate test of vision with the glasses >0.6. Refraction: Hypermetropic astigmatism. Movement of eyes in full range. Divergent strabismus 10–15 grad. by Girshberg. Horizontalnystagmus of medium range nystagmus at the side look. Pupils reaction for the light is vivid. The anterior part of eyes without pathology. Optical media transparent. In the bottom of the eyes: disci of optical nerves are shaped of pallid pink color. Arteries are narrow. Arteries/veins = 1/3. Veins are meandered. Solitary loci of dystrophy in the macular and central zones of the retina. Conclusion: Concomitant divergent strabismus. Middle range nystagmus. Hypermetropic astigmatism. Angiopathy of retina. Initial maculodystrophy of both eyes.
The state of the patient improved: diminished the weakness in arms and legs, decreased the hypertonia of neck muscles, muscles of the back, arms, and legs. Divergence of eyes decreased. Syndrome of early post transplantation improvement of general condition was observed. It gave the effect of immediate (the night after first transplantation) enhancement of the range of movement. The patient noted, that he had stand up several times without external help and could walk by himself around the ward. There were observed normalization of the sleep formula, increasing of appetite, work capacity, improvement of mood.
Taking into consideration apparent progress of the condition of Mr. D.C. we recommend continuing the course of cell therapy in 6–8 months.
We had an honour to accept at the clinic Clinic Mr. D.C., DOB November 3, 1959.
We have established the following diagnosis: Multiple sclerosis of cerebrospinal type. Concomitant divergent strabismus OS. Middle range nystagmus. Hypermetropic astigmatism. Angiopathy of retina. Initial maculodystrophy of both eyes.
Average blood count: Erythrocytes 4.6×1012/l, Hb 152 g/l. color index 1.0, thrombocytes 210×109/l, leukocytes 6.8×109/l, stab neutrophils 4%, segmented neutrophils 54%, eosinophiles 2%, lymphocytes 39%, monocytes 1%, ESR 3 mm/hr.
Blood Chemistry: Bilirubin total 21.7 mmol/l, direct neg., indirect 21.7 mmol/l, ALT 0.34 mmol/l, ACT 0.21 mmol/l, thymol test 1.7 units, urea 5.8 mmol/l, creatinine 0.062 mmol/l.
Blood glucose: 3.9 mmol/l.
Common urine analysis: Volume 60.0 ml, protein – neg., sugar – neg., flat epithelium in small quantity, leukocytes 2–3 in the field of vision.
ECG: Regular sinus rhythm. Normal position of the heart axis. Dystrophic changes in myocardium.
The patient’s health condition has gotten noticeably better, comparing to the previous examination (e.g. The patient is dressing himself and eating without help). The horizontal middle range nystagmus the by the side look is still continued, rhinolaly is decreased. Tonus in arms is normal, in legs – enhanced, s>d. Enhanced reflexes, s>d, both legs – Babinski’s sign. No disturbances of motional coordination found. The pain sensitivity is intact.
Conclusion: multiple sclerosis of cerebrospinal type. Recommended to continue the course of the cell therapy.
1st day. Implantation of the cell suspension sample 3038KM52 subcutaneously in the frontal abdomen in two depots in amount of 1.3 ml each.
2nd day. Implantation of the sample 3038K52 drop-wise intravenously in amount of 2.4 ml; implantation of the sample 3038KM52 subcutaneously in the frontal abdomen in two depots in amount of 0.7 ml each.
3rd day. Implantation of the sample 3038K52 dropwise intravenously in amount of 1.5 ml; implantation of the sample 3038KM52 subcutaneously in the frontal abdomen in two depots in amount of 1.5 ml each.
4th day. Implantation of the sample 3038B460 dropwise intravenously in amount of 2.2 ml; implantation of the sample 3038BM60 subcutaneously in the frontal abdomen in two depots in amount of 1.8 ml each.
Mr. D.C. is recommended to:
1. To make monthly peripheral blood counts.
2. To take the peripheral blood uncolored smears fixed by 960 spirits monthly. To keep these smears and give them all together over to the clinic.
3. To make the next visit to the clinic in 9–12 months.
We had honour to accept at the clinic Mr. D.C., DOB November 3, 1959. This is the third visit of Mr. D.C. to the clinic ). Previous courses of cell therapy (the first, the second) stopped progress of disease and gave certain amelioration of the state as noted below.
We have established the following diagnosis: Multiple sclerosis of cerebrospinal type with tetraparesis mostly expressed in legs, d>s. Concomitant divergent strabismus OS. Middle range nystagmus. Hypermetropic astigmatism. Angiopathy of retina. Initial maculodystrophy of both eyes.
Average blood count: Erythrocytes 4.4×1012/l, Hb 146 g/l. color index 1.0, thrombocytes 190×109/l, leukocytes 5.2×109/l, stebcellsstab neutrophils 3%, segmented neutrophils 65%, eosinophiles 2%, lymphocytes 22%, monocytes 8%, ESR 3 mm/hr.
Blood glucose: 4.3 mmol/l.
Blood Chemistry: Bilirubin total 15.1 mmol/l, direct – neg., indirect 15.1 mmol/l, ALT 0.38 mmol/l, ACT 0.21 mmol/l, thymol test 2.4 units, urea 6.9 mmol/l, creatinine 0.074 mmol/l.
Common urine analysis: Volume 120.0 ml, density 1020, transparent, light-yellow, protein – neg., sugar – neg., flat epithelium in small quantity, leukocytes – single in the field of vision.
ECG: Regular sinus rhythm. Normal position of the heart axis. Signs of dystrophic changes in myocardium.
The patient is admitted to the clinic third time the first, the second). The patient notes substantial improving of his condition: he stands up by himself, stays, periodically – walks with the help of a stick. Considerably improved the sight and hearing for the left ear. Diplopy passed away, there appeared possibility of visual load, including work with a computer. Last period the patient can be served by himself (meal, dressing, toilet, etc.).
Neurological status: Patient is in contact, adequate, oriented. Eye slots and pupils d=s, the movements of eye apples in full range, convergation satisfactory, periodically horizontal middle range exhaustion nystagmus. The face is symmetric. Tongue in the middle line. The range of active movements in arms is not limited. Tonus in arms is practically unchanged. Reflexes are enhanced, d>s, with enlargement of reflex zones. Strength in the legs diminished d>s, in distal parts more. Tonus in legs is increased substantially, more in flexors, more in the left leg. In the right leg tonus is combined due to “cerebellum” hypotony. Reflexes are high, without enlargement of reflex zones, clonus in feet is absent. Left plantar reflex. On the right side unconvincing Babinski’s sign. The pain sensitivity is intact, test for coordination executes sufficiently. Stays leaning upon the stick.
Conclusion: multiple sclerosis of cerebrospinal type with tetraparesis, d>s, mostly in legs, deterioration of walking.
Recommendation: to continue cell therapy.
Examination by ophthalmologist.
At the approximate test of vision with the glasses >0.6. Refraction: Hypermetropic astigmatism. Movement of eyes in full range. Divergent strabismus about 10 grad. according Girshberg. Horizontal medium range nystagmus at the side look. Pupils reaction for the light is vivid. Optical media transparent. In the of nervi opticinervifundus of the eyes: discs opticiof optical nerves are shaped of pallid pink color. Arteries are narrow. Arteries/venues = 1/3. Solitary loci of dystrophy in the macular and central zones of the retina.
Conclusion: Concomitant divergent strabismus. Middle range nystagmus. Hypermetropic astigmatism. Angiopathy of retina. Initial maculodystrophy of both eyes.
The 1st day. Transplantation of the sample 3038P513 drop-wise intravenously in amount of 2.0 ml; implantation of the sample 3038PM513 subcutaneously in the frontal abdomen in two depots in amount of 1.1 ml each.
The 2nd day. Transplantation of the sample 3038P513 drop-wise intravenously in amount of 1.6 ml; implantation of the sample 3038PM513 subcutaneously in the frontal abdomen in two depots in amount of 1.0 ml each.
The 3rd day. Transplantation of the sample 3038P134 drop-wise intravenously in amount of 2.1 ml; implantation of the sample 3038PM134 subcutaneously in the frontal abdomen in two depots in amount of 0.6 ml each.
The 4th day. Implantation of the sample 3038PM134 subcutaneously in the frontal abdomen in two depots in amount of 1.0 ml each.
The cell suspension samples 3038P513, 3038PM513, 3038P134 and 3038PM134 possessed the functional activity as mentioned above and are certified as follows:
|Bacterial sterility test||Negative|
|Test with cardiolipid antigen||Negative|
The treatment was tolerated well with no side effects.
The condition of the patient was improved: it was noted syndrome of early posttransplantation amelioration in a form of increasing of mental working capacity, improving of mood. Long term effects of the treatment are clear from neurologist description. It is time to train legs in the vertical position.
Mr. D.C. is recommended:
1. To continue cell therapy in the clinic in 9–12 months.
2. To use mechanotherapy for improving of movements, to make training in vertical position, including training in a swimming pool.
3. To try Sirdalud (Tizanidin), Sandoz, 0.002 1/2 of the tablet to control and diminish remove hypertonia first at repose in sitting pose, then at the movements of legs.
The patient H. feedback after the second course of stem cell treatment
Diagnosis: Multiple sclerosis
Dates of the treatment: November 2001; May 2009; May 2010
The patient underwent the first course of stem cell treatment in 2001. After the treatment, positive results were achieved, and the patient H. didn’t need top-ups for the next 8 years.
The second course of stem cell treatment was carried out in May 2009.
Right after return home, Mr. H. has noticed the following improvements:
“On May 9 I had my first instant success at home: from airport I travelled by car to my home. We live on the second floor. Without thinking about climbing stairs as usual (I need the handrail absolute) I arrived in my flat and was very happy that it was as easy as 12 years ago”.
Five months after the second course of embryonic stem cell treatment patient H. wrote the following:
As you described before, at present, I find myself in the second phase of posttransplantation effects when the amount of stem cells has increased in the organs and systems. In this connection, I would like to ask Doctor Smikodub once again about the restoration of myelin he told me during our first conversation before the beginning of the treatment.
We live on the second floor of the 12-apartment house, and for a long time we thought over the idea to move to another apartment, and 4 weeks ago we did so. When you move to a new apartment you have to pack a lot of boxes and properly organize everything for the move in advance. All these things were stressful for me and frightened me for many years, therefore, I didn’t want to move anywhere. But due to my problems with the gait we had to take the decision to move to a new apartment. As my parents live 350 km from our place and my wife’s parents are not healthy enough to carry heavy things and fulfil other important tasks, we had to clench our teeth and do everything ourselves.
And you know what: my wife was so surprised and amazed that I managed to make so many efforts and could do everything without anyone’s assistance just like a healthy man. My wife insisted on somebody’s help but I didn’t want anyone to be on my way as I proffered to do everything myself, and I did manage to cope with everything. And now, looking back, I understand that within the last years even small efforts always made me “unfit for action”. (In 2008, we could manage with the move to another apartment only if somebody helped us). Thus, in the beginning of August we started to prepare our new apartment for living and as I had no problems with that, I continued with packing our belongings and prepared everything for our move. And after we have moved to the new apartment I began to unpack our things. Now we live on the ground floor and have a small garden next to our house.
Despite our move to the new apartment and all the related efforts I didn’t feel exhausted and I couldn’t believe that my condition would develop even better than some months ago.
I would like to tell you one more thing: my capacity for work has improved, and such signs of multiple sclerosis as the beginning numbness in my fingertips and continuous fatigue have almost disappeared. I can’t believe that everything goes on this way but the transplantation of stem cells works and works…:)
I would like to thank you once again for letting me come to Kiev again, and I am amazed with what you have done for my health. I really have the impression that this time MS will stop forever.
Next time I will forward you my new health update.
The feedback of the patient V.A. after the course of stem cell treatment of multiple sclerosis
Diagnosis: Multiple sclerosis
Date of the treatment: June 2010
The patient V. A. underwent a course of multiple sclerosis stem cell treatment. After returning home, he wrote us the following:
Right after the arrival from the clinic, I stopped to pull the left leg. At present I walk more on my own. Weakness in the arms and legs has decreased, and my gait has become more confident.
In early July, I noticed that I could see better and more clearly, and I’m able to recognize people I’m familiar with from afar. In the middle of July I was able to read. My vision has been improving each day.
On July 20 I was able to swim a little, while earlier I could not.
My appetite improved.
Yours, V. A.
Testimonial after the first course of treatment at the clinic
Diagnosis: Cerebrospinal primary progressive multiple sclerosis with pyramidal insufficiency in the right, incontinence, EDSS – 4. Stage I grade 2 COPD (chronic obstructive pulmonary disease), diffuse pneumosclerosis. Emphysema. Pulmonary insufficiency 0.
Date of treatment: February 2011.
Hello, doctors and staff at the clinic!
Sorry I have not written before but much has happened in my life.
Primarily I feel good.
There is now more power in my arms and hands. I feel there is more power in my legs, although I would like to have more power in them. Now I can train some muscles which I could not get under control before, and I hope I can still train myself to become better, there is also more power in my voice and I get much fewer seizures than before.
So I’m happy with what I have achieved by being over at you clinic, and I would like to thank for a very good stay at your clinic.
Afterthought to her, the little black-haired neurologist (can not remember her name) that I have also quit with smoking! (nearly 3 months)
Testimonial of L.N. after the first course of stem cell treatment
Diagnosis: Secondary progressive cerebrospinal multiple sclerosis with spastic paraparesis of lower extremities. Urine incontinence. EDSS – 7.5.
Date of treatment: 24-25 September 2012
Dear the clinic doctors,
It has been one month since my first stem cell treatment (24.09.12) so here is an update as promised. Apart from a week of jet-lag on my return to Australia, I have generally been feeling quite good and have actually noticed a few small improvements!
Firstly, bowel and bladder function seems to have improved in that the intense urgency to urinate has lessened to a much more normal sensation and I have been using a mild herbal laxative to increase bowel movements. Whereas I could only manage one to two bowel motions per week, this has now increased to three to four per week.
Secondly, I now have an appetite. Before having treatment I never used to feel hunger but now it is common for me to wake up feeling hungry and then again prior to my evening meal.
I also seem to be sleeping much better and not waking several times during the night, unable to get back to sleep. I average around 8 hours of deep sleep per night and I feel SO much better for being able to sleep well!
I am continuing to take all my nutritional supplements and have increased my intake of protein in my diet so hopefully the repeat of my blood test (due late December) will show an improvement in protein levels.
I’d just like to take this opportunity to thank you once again for the fantastic care you took of me and my daughter while we were visiting your clinic. ALL the clinic staff made us feel so welcome, safe and cared for – we’re both very much looking forward to meeting you all again!
If there is anything further you wish to know, please don’t hesitate to contact me.
Thank you so much,
Feedback of the patient with multiple sclerosis after stem cell treatment
Country: Republic of Serbia
Diagnosis: Remitting-relapsing multiple sclerosis, EDSS – 3.
Treatment dates: May 10-11, 2012
Good day, Dream team 🙂
Greatings from Belgrade and R.Srbija.
Thanks for asking for updates and sorry for delay in the responding of the same.
We were to ocupate having a normal and healthy life 🙂 D. can not compare her life before and after meeting your team.
We just want to thank you a million on the all service and help that you have been provide to her.
She is feeling excelent, working without any issues and all thoughts about health issues are gone from her mind.
Please find attached document that you request in the email,
If we need to do anything else, please let us know.
Have a nice and safe day.
Thanks a million!!!
R.W. feedback on multiple sclerosis treatment at the clinic
Diagnosis: Primary progressive cerebrospinal multiple sclerosis with spastic paraparesis of the lower extremities. Urine incontinence.
Dates of treatment: September 20-21, 2012
R.W. was treated with stem cells in our clinic. Below is his feedback on the treatment.
October 19, 2012
I just wanted to write a little status report on how I feel and why the test results are pending. I feel really good both physically and mentally in addition to my Swedish doctors do not want to or cannot help me with my blood samples but I have not given up yet, I try with other doctors and hope for better help. I will be back with test results as soon as I can and until that I train and eat so right I can according to your wish.
Best regards, R.W.
November 12, 2012
I feel pretty good after the treatment.
I have not got any pain in my legs since the treatment and my legs feel stronger and I am not that tired in the afternoon.
It feels like it’s easier to lift my left foot than before.
I will get back to you with blood sample results as soon as possible–it’s not that easy to get them done in Sweden.
November 20, 2012
I would like to announce that now 2 months after the treatment in Kiev, I have improved in every way. I feel stronger and less tired. But I have also encountered a problem with getting help to get follow-up blood tests in Sweden, according to the Ukrainian doctors wishes. So my curiosity is if I and my brother are the first MS sick Swedes who go through this treatment and unless we are first, my wonder is how other Swedes have done to get help with testing. Do the clinic have a partner for sampling in Sweden?
Grateful for the response, best regards R.W.
Condition of the patient M.C. with multiple sclerosis
Diagnosis: Secondary progressive multiple sclerosis with cerebrospinal involvement, spastic paraparesis of lower extremities and urine retention. EDSS – 4,5-5. Vertebrogenic dorsopathy with moderate pain
Dates of treatment: September 30 – October 4, 2013.
It has been 1 month since M. was treated at your clinic for Secondary Progressive Multiple Sclerosis. We will be sending additional updates on a monthly basis. So far, she has experienced the following improvements in her symptoms:
- She had 2 painful spots on her spine. Middle of spine spot is completely gone. Lower back spot is no longer painful. Only a moderate amount of pressure remains.
- Improved leg muscle strength. Has been able to stand up from a sitting position much easier and has been able to increase distance walking with walker.
- Increased energy level.
- Sleeping very well with 3mg. of Melatonin. We have eliminated Tylenol PM for sleeping.
- Bottom of feet remain less picky and painful. Feels like walking on smooth pebbles.
- Friends and neighbors have commented that M. looks more vibrant and interested in activities.
- A short time after treatment M. felt movement in her stomach area that lasted for about 3 days.
In addition to the above improvements following are the lifestyle changes M. has made:
- Increased intake of Protein.
- Increased exercise from 3 days per week to daily. Exercise includes 13 minutes of riding recumbent bike that exercises upper and lower body and 11 minutes of stretching.
- Planning to incorporate pool exercise soon.
- Appetite has not changed.
Blood test results, requested by the clinic doctor, are in the process of being sent to us. We will forward to you as soon as we get them.
We look forward to additional improvements as we approach the 1 to 6 month timeframe where most improvements may occur. Please feel free to comment on any of the above information and give us additional direction as deemed necessary.
Is the progress M. has experienced typical of most MS patients?
Feedback of MS patient after the stem cell therapy at the clinic
Country: Kingdom of Saudi Arabia
Diagnosis: Secondary progressive multiple sclerosis with cerebrospinal involvement and spastic paraparesis of the lower extremities and urine retention, EDSS – 4-4,5.
Dates of treatment: September 12-13, 2013
so good to hear from you, hope you are all doing well.
I’m feeling much better and more energetic. My workability has improved quite much. The numbness almost vanished. I barely feel the stiffness and creeping sensation in the lower extremities but I noticed it on the right leg as a new symptom. The balancing has improved, as well as the memory and concentration. The urine retention has not improved yet.
Report on B. B. condition after the stem cell therapy
Patient: B. B.
Diagnosis: Secondary progressive multiple sclerosis with cerebrospinal involvement and spastic paraparesis of the lower extremities. EDSS – 5,0. Urine incontinence. Moderate type 1 diabetes mellitus
Dates of treatment: November 12-13, 2013 (2nd course)
Dear the clinic,
Thank you for the fantastic care you took of me and my husband while we were visiting your clinic. We felt very welcome.
I feel pretty good after the treatment. I feel like it’s easier to lift my right leg and both my legs feel stronger. Also my balance feels better. But I feel a bit unsure of my stability.
Overall I feel much happier and I have energy to do more of the training. Tomorrow I think about swimming if I still have the energy. I can walk much longer without support now than before the treatment. My back pain has disappeared, but I still feel a little week in my back.
I will send you the blood samples as soon as possible. It’s not so easy to get them here in Finland but I will try.
Overall I feel stronger and happier.
Greetings, B. B.
Feedback of the patient with multiple sclerosis after stem cell treatment at the clinic
Diagnosis: Primary progressive (most likely) multiple sclerosis with cerebral involvement and moderate paraparesis of the lower extremities. Urine incontinence.
Dates of treatment: August 4 -7, 2014
Dear all at the clinic,
I would like to say thanks a lot to all at the clinic, where I was in last week.
I have only met professional and kind doctors and other staff. A very important thing I felt, was that the clinic really took my situation seriously and also, that the fetal stem cell treatment is given individually.
With my disease in mind, I have – of course – not felt anything as to getting it better. But my major goal was also to stop the progression of my multiple sclerosis.
Once again, thank you all at the clinic. I hope to see you all next year for my second treatment. I am convinced that stem cell treatments will help me to stop getting it worse and worse due to my disease.
47 year old male from Denmark with MS – diagnosis in 2002.
Report on the condition of a multiple sclerosis patient after stem cell treatment at the clinic
Diagnosis: Primary progressive multiple sclerosis with cerebrospinal involvement, spastic paraparesis of lower extremities, urine incontinence. Bedsore on the sacrum.
Dates of treatment: May 13-15, 2014
I would like to send you an update on R’s behalf. R has experienced a miraculous result from her stem cell treatment. Not only did her back wound entirely heal over within 120 days of the treatment (her doctor told her it would never heal and could only be managed as it was so deep), but more importantly her chronic pain problems of 3 years began to go down dramatically after the treatments and disappeared entirely within 75 days. Her pain was crippling and felt like rusty barbed wire being dragged through holes in her legs, and now her body is free of pain!!!! She has stopped taking all of her medications as they are no longer needed!
R. plans to come back to Kiev in the spring and is now trying to raise funds to come back again.
Thank you for your wonderful treatments!